

RECEIVED
CENTRAL FAX CENTER


AUG 12 2008

I. Amendments to the Claims

This listing of claims replaces without prejudice all prior versions, and listings, of claims in the present application.

Listing of Claims:

1. (Previously Amended) A compound of Formula I, or a salt thereof:



wherein

R^1 , R^2 and R^3 are each independently selected from H, OH, C₁₋₆alkyl, C₁₋₆alkoxy, NH₂, NH-C₁₋₆alkyl, N(C₁₋₆alkyl)(C₁₋₆alkyl), SH, S-C₁₋₆alkyl, NO₂, CF₃, OCF₃ and halo;

R^4 is unsubstituted Ar, or Ar substituted with 1-4 substituents, independently selected from C₁₋₆alkyl, C₁₋₆alkoxy and halo;

X is selected from (CH₂CH₂O)_n and (CH₂)_n, and

n = 1-4.

2. (Original) The compound according to claim 1, wherein

R^1 , R^2 and R^3 are each independently selected from H, OH, C₁₋₄alkyl, C₁₋₄alkoxy, NH₂, NH-C₁₋₄alkyl, N(C₁₋₄alkyl)(C₁₋₄alkyl), NO₂, CF₃, OCF₃ and halo;

R^4 is C₁₋₆alkyl,

X is $(\text{CH}_2\text{CH}_2\text{O})_n$, and

n = 1-4.

3. (Previously Amended) The compound according to claim 1, wherein R^1 , R^2 and R^3 are each independently selected from H, OH, C_{1-4} alkyl, C_{1-4} alkoxy, NH_2 , NH-C_{1-4} alkyl, $\text{N}(\text{C}_{1-4}\text{alkyl})(\text{C}_{1-4}\text{alkyl})$, NO_2 , CF_3 , OCF_3 and halo.
4. (Original) The compound according to claim 3, wherein R^1 , R^2 and R^3 are each independently selected from H, OH, OCH_3 , NH_2 , $\text{N}(\text{CH}_3)_2$ and NO_2 .
5. (Original) The compound according to claim 4, wherein R^1 , R^2 and R^3 are each independently selected from H, OH, and OCH_3 .
6. (Original) The compound according to claim 1, wherein R^4 is unsubstituted Ar.
7. (Original) The compound according to claim 6, wherein R^4 is phenyl.
8. (Original) The compound according to claim 2, wherein R^4 is methyl or ethyl.
9. (Original) The compound according to claim 8, wherein R^4 is methyl.
10. (Original) The compound according to claim 9, wherein n is 2-3.
11. (Original) The compound according to claim 10, wherein n is 3.

12. (Original) A compound selected from:

2-Cyano-5-(4-hydroxy-3,5-dimethoxyphenyl)-penta-2E,4E-dienoic acid benzyl ester (CRIX-38)

2-Cyano-5-(3,4-dihydroxyphenyl)-penta-2E,4E-dienoic acid benzyl ester (CRIX-39)

2-Cyano-5-(3,4-dihydroxyphenyl)-penta-2E,4E-dienoic acid 2-[2-(2-methoxyethoxy)ethoxy]
ethyl ester (CRIV-42)

2-Cyano-5-(4-hydroxy-3,5-dimethoxyphenyl)-penta-2E,4E-dienoic acid 2-[2-(2-
methoxyethoxy)ethoxy]ethyl ester (CRIV-46); and

2-Cyano-5-(4-hydroxy-3-methoxyphenyl)-penta-2E,4E-dienoic acid benzyl ester (CRIX-79).

13. (Original) A composition comprising a compound according to any one of claims 1 to 12
in admixture with a pharmaceutically acceptable diluent or carrier.

14. (Canceled).

15. (Canceled).


16. (Canceled).

17. (Original) A method of modulating cell proliferation comprising administering an
effective amount of a compound according to any of claims 1-12, and/or a composition according
to claim 13, to a cell or animal in need thereof.

18. (Original) The method according to claim 17, for inhibiting cell proliferation.

19. (Original) The method according to claim 18 wherein the cell is a malignant hematopoietic cell.

20. (Withdrawn) A compound of Formula III, and/or a salt, solvate, or hydrate thereof:



wherein

R^1 , R^2 and R^3 are each independently selected from H, OH, C_{1-6} alkyl, C_{1-6} alkoxy, NH_2 , $NH-C_{1-6}$ alkyl, $N(C_{1-6}alkyl)(C_{1-6}alkyl)$, SH, $S-C_{1-6}alkyl$, NO_2 , CF_3 , OCF_3 and halo; and

R^4 is selected from C_{1-6} alkyl, phenyl and pyridyl, wherein phenyl and pyridyl are unsubstituted or substituted with 1-4 substituents, independently selected from C_{1-6} alkyl, C_{1-6} alkoxy and halo, with the provisos that when R^1 and R^3 are both H and R^4 is unsubstituted phenyl, R^2 is not H, Cl, or OCH_3 ; when R^1 and R^2 are both H and R^4 is unsubstituted phenyl, R^3 is not NO_2 ; and when R^1 and R^3 are both H and R^4 is CH_3 , R^2 is not $N(CH_3)_2$.

21. (Withdrawn) The compound according to claim 1, wherein R^1 , R^2 and R^3 are each independently selected from H, OH, C_{1-4} alkyl, C_{1-4} alkoxy, NH_2 , $NH-C_{1-4}alkyl$, $N(C_{1-4}alkyl)(C_{1-4}alkyl)$, NO_2 , CF_3 , OCF_3 and halo.


22. (Withdrawn) The compound according to claim 21, R^1 , R^2 and R^3 are each independently selected from H, OH, OCH_3 , NH_2 , $N(CH_3)_2$ and NO_2 .

23. (Withdrawn) The compound according to claim 20, wherein R^4 is selected from C_{1-4} alkyl, phenyl and pyridyl.
24. (Withdrawn) The compound according to claim 23, wherein R^4 is selected from CH_3 and phenyl.
25. (Withdrawn) The compound according to claim 24, wherein R^4 is unsubstituted phenyl.
26. (Withdrawn) The compound according to claim 20, wherein phenyl and pyridyl are unsubstituted or substituted with 1-3 substituents, independently selected from C_{1-4} alkyl, C_{1-4} alkoxy and halo.
27. (Withdrawn) The compound according to claim 24, wherein phenyl is unsubstituted or substituted with 1-2 substituents, independently selected from C_{1-4} alkyl, C_{1-4} alkoxy and halo.
28. (Withdrawn) The compound according to claim 20, wherein at least one of R^1 , R^2 and R^3 is OH while R^4 is selected from unsubstituted phenyl and phenyl substituted with 1-4 substituents, independently selected from C_{1-6} alkyl, C_{1-6} alkoxy and halo.
29. (Withdrawn) A compound selected from:
- 2-Benzenesulfonyl-5-(3,4-dihydroxyphenyl)-penta-2E,4E-dienenitrile (CRVIII-33),
- 2-Benzenesulfonyl-5-(4-hydroxy-3,5-dimethoxyphenyl)-penta-2E,4E-dienenitrile (CRVIII-34),
- 2-Benzenesulfonyl-5-(4-nitrophenyl)-penta-2E,4E-dienenitrile (CRVIII-35),
- 5-(3,4-Dihydroxyphenyl)-2-(pyridine-2-sulfonyl)-penta-2E,4E-dienenitrile (CRVIII-50),

2-(4-Chlorobenzenesulfonyl)-5-(3,4-dihydroxyphenyl)-penta-2E,4E-dienitrile (CRVIII-51),
5-(3,4-Dihydroxyphenyl)-2-(toluene-4-sulfonyl)-penta-2E,4E-dienitrile (CRVIII-52), and
5-(3,4-Dihydroxyphenyl)-2-methanesulfonyl-penta-2E,4E-dienitrile (CRVIII-53).

30. (Withdrawn) A composition comprising a compound according to any one of claims 20 to 29 in admixture with a pharmaceutically acceptable diluent or carrier.

31. (Withdrawn) A composition comprising, in admixture with a pharmaceutically acceptable diluent or carrier, a compound of Formula IV, and/or a salt, solvate or hydrate thereof:



wherein

R^1 , R^2 and R^3 are each independently selected from H, OH, C_{1-6} alkyl, C_{1-6} alkoxy, NH_2 , $NH-C_{1-6}$ alkyl, $N(C_{1-6}alkyl)(C_{1-6}alkyl)$, SH, $S-C_{1-6}alkyl$, NO_2 , CF_3 , OCF_3 and halo; and


R^4 is selected from C_{1-6} alkyl, phenyl and pyridyl, wherein phenyl and pyridyl are unsubstituted or substituted with 1-4 substituents, independently selected from C_{1-6} alkyl, C_{1-6} alkoxy and halo.

32. (Canceled).

33. (Canceled).

34. (Canceled).

35. (Withdrawn) A method of modulating cell proliferation comprising administering to a cell or animal in need thereof an effective amount of a composition according to any of claims 30 and 31, and/or a compound capable of modulating cell proliferation of Formula IV, and/or a salt, solvate or hydrate thereof:



wherein

R^1 , R^2 and R^3 are each independently selected from H, OH, C_{1-6} alkyl, C_{1-6} alkoxy, NH_2 , $NH-C_{1-6}$ alkyl, $N(C_{1-6}alkyl)(C_{1-6}alkyl)$, SH, $S-C_{1-6}alkyl$, NO_2 , CF_3 , OCF_3 and halo; and

R^4 is selected from C_{1-6} alkyl, phenyl and pyridyl, wherein phenyl and pyridyl are unsubstituted or substituted with 1-4 substituents, independently selected from C_{1-6} alkyl, C_{1-6} alkoxy and halo.

36. (Withdrawn) The method according to claim 35, for inhibiting cell proliferation.

37. (Withdrawn) The method according to claim 36, wherein the cell is a malignant hematopoietic cell.

38. (Previously Presented) The compound according to claim 1 in substantially anhydrous form.

39. (Previously Presented) The compound according to claim 1 in crystalline form.